Sana Biotechnology, Inc. (SANA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Sana Biotechnology is a clinical-stage biotechnology company developing engineered cell therapies for Type 1 Diabetes, B-cell mediated autoimmune diseases, and oncology. The company operates as an emerging growth company and is currently in a development phase with no commercial product revenue.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(93.8) million | $(50.3) million | $(143.2) million | $(157.8) million |
| Loss Per Share (Basic/Diluted) | $(0.39) | $(0.21) | $(0.60) | $(0.70) |
| Operating Expenses | $95.0 million | $49.4 million | $145.6 million | $160.1 million |
| Cash & Cash Equivalents | $71.3 million | $127.6 million (Dec 2024) | $71.3 million | $127.6 million (Dec 2024) |
| Total Liquidity (Cash + Marketable Securities) | $72.7 million | $152.5 million (Dec 2024) | $72.7 million | $152.5 million (Dec 2024) |
| Accumulated Deficit | $(1.75) billion | $(1.60) billion (Dec 2024) | $(1.75) billion | $(1.60) billion (Dec 2024) |
Material Changes vs. Prior Period
- Impairment Charges: The company recorded a significant non-cash impairment loss of $44.6 million in Q2 2025 related to long-lived assets (construction in progress, laboratory equipment, and leasehold improvements) at its Bothell and Seattle facilities. This was driven by a decision to suspend further build-out of internal manufacturing capabilities in favor of third-party CDMOs.
- Operating Expenses: Total operating expenses increased to $95.0 million in Q2 2025 from $49.4 million in Q2 2024, primarily due to the $44.6 million impairment charge. Excluding this charge, operating expenses decreased due to portfolio prioritization and workforce reductions announced in November 2024.
- Success Payments & Contingent Consideration: The company recognized an expense of $10.3 million in Q2 2025 related to changes in the fair value of success payment liabilities and contingent consideration (Cobalt and Harvard agreements), compared to a gain of $27.9 million in Q2 2024.
- Cash Position: Cash and cash equivalents decreased by approximately $56.3 million from the beginning of the year to June 30, 2025, driven by net cash used in operating activities of $81.8 million.
Guidance, Outlook, and Risks
- Liquidity & Capital Resources: As of June 30, 2025, the company held $72.7 million in cash and marketable securities. Management believes this, combined with proceeds from a subsequent public offering in August 2025 ($70.0 million net) and an At-The-Market (ATM) facility ($28.6 million net raised post-period), is sufficient to fund operations for at least one year from the filing date.
- Portfolio Prioritization: The company continues to focus on Type 1 Diabetes (SC451), B-cell mediated autoimmune diseases (SC291, SC262), and in vivo CAR T cells (SG299). Development of SC291 in oncology and the glial progenitor cell program (SC379) was suspended to seek partnerships.
- Clinical Updates: Positive six-month results were announced for the UP421 investigator-sponsored trial for Type 1 Diabetes, showing survival and function of transplanted beta cells without immunosuppression. Data from the GLEAM (SC291) and VIVID (SC262) trials are expected in 2025.
- Risks: Key risks include the need for additional financing, the uncertainty of clinical trial outcomes, the complexity of manufacturing cell therapies, and potential fluctuations in net loss due to fair value adjustments of contingent consideration liabilities.
Investor Verification Checklist
- Subsequent Financing: Verify the details and net proceeds of the August 2025 underwritten public offering ($70.0 million) and the post-period ATM sales ($28.6 million) to confirm the updated cash runway.
- Manufacturing Strategy: Confirm the extent of the reliance on third-party CDMOs following the impairment of internal manufacturing assets and the impact on future capital expenditures.
- Contingent Liabilities: Monitor the fair value of the Cobalt Contingent Consideration ($117.1 million) and Success Payment liabilities ($8.6 million), as fluctuations in stock price and market cap can cause significant volatility in reported net loss.
- Legal Proceedings: Review the status of the putative securities class action lawsuit filed in March 2025 regarding alleged false statements about the company's business and prospects.
- Clinical Milestones: Track the timing of data readouts for the GLEAM and VIVID trials and the IND filing timeline for SC451 and SG299.